Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	13.36	13.8	16.02	16.89	13.07	11.39
Revenue Growth (YoY)	-17.70%	-13.87%	-5.10%	29.23%	14.68%	200.43%
Cost of Revenue	5.49	5.53	6.01	4.28	2.65	2.74
Gross Profit	7.87	8.27	10.02	12.6	10.41	8.66
Selling, General & Admin	23.35	24.95	34.38	31.34	18.4	18.48
Other Operating Expenses	0.45	0.62	0.67	1.64	4.05	0.75
Operating Expenses	23.8	25.57	35.05	32.99	22.45	19.23
Operating Income	-15.93	-17.3	-25.03	-20.38	-12.04	-10.58
Interest Expense / Income	0	0	0	0.01	0.1	0.14
Other Expense / Income	-0.29	-3.71	-1.19	-0.11	-0.08	0.04
Pretax Income	-15.64	-13.58	-23.85	-20.29	-12.06	-10.75
Net Income	-15.64	-13.58	-23.85	-20.29	-12.06	-10.75
Preferred Dividends	0	0	0	0	5.93	1
Net Income Common	-15.64	-13.58	-23.85	-20.29	-17.99	-11.75
Shares Outstanding (Basic)	2	1	1	1	1	0
Shares Outstanding (Diluted)	2	1	1	1	1	0
Shares Change	132.99%	32.46%	8.39%	65.00%	4.36%	6.78%
EPS (Basic)	-10.93	-11.14	-25.90	-24.00	-35.00	-23.75
EPS (Diluted)	-10.93	-11.14	-25.90	-24.00	-35.00	-23.75
Free Cash Flow	-11.64	-12.8	-20.51	-18.13	-5.8	-5.52
Free Cash Flow Per Share	-5.04	-10.50	-22.28	-21.35	-11.27	-11.18
Gross Margin	58.90%	59.93%	62.52%	74.65%	79.70%	75.99%
Operating Margin	-119.21%	-125.32%	-156.21%	-120.71%	-92.15%	-92.84%
Profit Margin	-117.06%	-98.42%	-148.81%	-120.15%	-137.67%	-103.17%
Free Cash Flow Margin	-87.09%	-92.74%	-128.00%	-107.38%	-44.39%	-48.42%
EBITDA	-15.05	-12.96	-23.18	-19.54	-11.24	-9.87
EBITDA Margin	-112.63%	-93.92%	-144.63%	-115.73%	-86.05%	-86.59%
Depreciation & Amortization	0.59	0.62	0.67	0.73	0.72	0.75
EBIT	-15.64	-13.58	-23.85	-20.27	-11.96	-10.62
EBIT Margin	-117.06%	-98.42%	-148.81%	-120.07%	-91.54%	-93.18%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).